Credit markets are sending mixed signals as spreads on the riskiest junk bonds have surged, while less risky corporate bonds remain relatively stable. This unusual divergence has left investors uncertain and cautious, with some describing the situation as "uncharted territory." The surge in riskier bond spreads could indicate growing concerns about credit risk, even though broader market stress appears contained for now. Investors will be watching closely to see if this trend signals deeper credit market issues ahead.
Credit markets entering uncharted territory provide context for Pluang's market snapshot as of Oct 20, 2026 03:01 WIB: Among 150 priced US stocks tradable on Pluang, 63 rose and 86 fell today. Notable movers include NVAX (Novavax Inc) at USD 11.19 with a 1-day change of -12.71% and a typical hold time of 59 days, FCEL (FuelCell Energy Inc) at USD 12.90 down 8.45% with a 48-day hold, and ASX (ASE Technology Holding Co Ltd) at USD 38.75 down 7.50% with a 49-day hold time. Pluang order activity shows NVAX with 36% Sell / 64% Buy, FCEL with 38% Sell / 62% Buy, and ASX with 22% Sell / 78% Buy.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
